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Members of the DEAD-box family of helicases, distinguished by a core characteristic sequence of Asp-Glu-
Ala-Asp, are expressed in a wide range of prokaryotes and eukaryotes and exhibit diverse cellular functions,
including DNA transcription, recombination and repair, RNA processing, translation, and posttranslational
regulation. Although ubiquitous, the function of most DEAD-box proteins is unknown. We and others have
recently cloned DP103, which harbors conserved DEAD-box, helicase, and ATPase domains in its N terminus.
DP103 (also termed Gemin3 and DDX20) interacts with SF-1, SMN, EBNA2, and EBNA3C in mammalian
cells. Here we demonstrate that a discrete domain within the nonconserved C-terminal region of DP103 directly
interacts with SF-1. This domain exhibits an autonomous repression function and is necessary and sufficient
for repressing the transcriptional activity of SF-1. Furthermore, intact DP103 exhibits helicase activity.
Importantly, the C-terminal domain is obligatory but not sufficient for this unwinding activity of DP103.
Together, our results support a novel paradigm for transcriptional repression and demonstrate the bifunc-
tional role of the C-terminal domain of DP103.
Members of the expanding family of DEAD-box proteins
are found in diverse organisms, including viruses, bacteria, and
eukaryotes from yeast to humans (30, 36). Proteins from this
family are characterized by a core segment of similarly spaced
conserved motifs. Among these motifs are ATPase motifs I
(AXXGXGKS/T) and II (Asp-Glu-Ala-Asp, D-E-A-D; hence
the family name), also known as Walker motifs A and B,
respectively (66), which are responsible for binding the nucle-
otide triphosphate-Mg2 complex (69). Additionally, motif III
is defined as a helicase domain, and motif VI is thought to bind
nucleic acids (reviewed in reference 33). Whereas ATPase
motifs exhibit a similar biochemical function, the activity of
other motifs, including helicase, remains conjectural for most
family members. Besides the core segment region that contains
the conserved motifs, the N- and C-terminal regions of indi-
vidual DEAD-box proteins exhibit little or no sequence ho-
mology to each other. This modular organization suggests that
the core region harbors conserved functions, whereas the N
and C termini may play a role in protein-specific functions.
These specialized functions may include discriminatory dock-
ing sites for proteins and/or additional RNA-binding motifs
that confer substrate specificity or direct the DEAD-box pro-
tein to selective subcellular localization (13). Helicases are
capable of unwinding duplex DNA or RNA in the presence of
energy derived from nucleotide triphosphate hydrolysis. These
enzymes are required for all aspects of nucleic acid metabolism
in both prokaryotes and eukaryotes. They are involved in DNA
repair, replication, recombination and transcription, RNA pro-
cessing, transcript stability, and translation initiation (13, 16,
19, 52). DEAD-box proteins commonly display RNA helicase
activity (12).
Several groups, including our own, have recently cloned
DP103, a protein of 825 amino acids (aa) that contains the
DEAD-box conserved region at the N terminus. Grundhoff et
al. (20) identified DP103 by virtue of its interaction with Ep-
stein-Barr virus nuclear antigens EBNA2 and EBNA3C and
demonstrated its intrinsic ATPase activity. In addition, DP103
(also termed Gemin3 and DDX20) was found to directly in-
teract with spinal muscular neuron (SMN) protein (5, 6, 65).
Nevertheless, the function of DP103 in these contexts re-
mained unclear. In the pursuit of mechanisms that modulate
the transcriptional activity of the orphan nuclear receptor ste-
roidogenic factor 1 (SF-1), we identified a previously unknown
repression domain within SF-1 (42). Using this repression do-
main as bait in a yeast two-hybrid approach we cloned from a
rat ovary library a novel regulator of SF-1, which is a murine
homologue of DP103 (42). We found that DP103 is ubiqui-
tously expressed at a low level, with higher expression predom-
inantly in steroid-producing murine tissues, which also express
SF-1 (42). Importantly, SF-1, EBNA2/EBNA3C, and SMN
interact with DP103 via the nonconserved C-terminal region of
DP103 (5, 20, 65), suggesting that this region is capable of
forming protein complexes and potentially functions in a man-
ner distinct from that of the conserved N-terminal DEAD-box
core domain. Only one DEAD-box protein, p68, has been
previously shown to interact with a member of the nuclear
receptor superfamily (17). p68 binds the N-terminal AF-1 do-
main of an estrogen receptor and enhances its transcriptional
activity. In contrast, DP103 interacts with the C-terminal re-
pression domain of SF-1 and diminishes its transcriptional
activity (42).
SF-1 is essential for endocrine and reproductive system de-
velopment and function (22, 43, 48). Mice harboring a targeted
disruption of the SF-1 gene lack gonads and adrenal glands,
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which consequently leads to early neonatal death from adrenal
insufficiency (3, 37, 49, 53). Additionally, the ventromedial
hypothalamic nucleus fails to fully develop in these mice, as do
the pituitary gonadotropes (26, 71). Molecular analysis re-
vealed that SF-1 regulates the expression of many steroido-
genic enzymes (P450scc, P450c17, P450c21, P450c11, P450arom,
and 3-hydroxysteroid dehydrogenase) (39, 43, 48) and other
pivotal regulators of endocrine and reproductive function, in-
cluding steroidogenic acute regulatory protein (StAR), Mulle-
rian inhibitory substance, gonadotropin-releasing hormone re-
ceptor, and luteinizing hormone- (reviewed in references 22,
43, and 48). The well-synchronized expression of these proteins
suggests that they are tightly modulated by SF-1 and possibly
by additional regulatory proteins. Nevertheless, the mecha-
nisms that govern SF-1 action are incompletely understood.
SF-1 is an orphan receptor that binds its DNA response ele-
ments as a monomer and thus is not a target for modulation by
a DNA binding heterodimerized partner (31, 38, 68). We and
others have previously identified several SF-1 domains that
modulate its activity through interactions with coregulators.
These include the C-terminal AF-2 hexamer, interacting with
SRC-1/CBP (12, 28); the distal repression domain, interacting
with DAX-1 and the nuclear receptor corepressor (N-CoR)
(11, 27); and the proximal interaction domain, interacting with
both SRC-1 and DAX-1 (11, 12). Also vital for SF-1 function
are serine203, which interacts with GRIP1 (23), and the pro-
line-rich region near the DNA binding domain (35).
Repression of SF-1 activity by a DEAD-box protein consti-
tutes a novel regulatory pathway, which may prove relevant to
endocrine and reproductive homeostasis. To elucidate the bi-
ological action of DP103 we sought to analyze the repression of
SF-1 by DP103. Here we mapped the domain that physically
interacts with SF-1 to aa 721 to 825 within the nonconserved
C-terminal region of DP103. Furthermore, we demonstrated
that this domain is necessary and sufficient for the repression
function of DP103. We also found that DP103 exhibits RNA
helicase activity and that the nonconserved C-terminal region
is obligatory for this activity.
MATERIALS AND METHODS
Plasmids. Murine SF-1 cDNA was described previously (12). pBS-SF-1wt and
pBSK-SF-1 mAAEY were generated as previously detailed (42). Full-length
DP103 (aa 1 to 825) and a series of deletion mutants (aa 1 to 410, 411 to 825, 411
to 617, 411 to 521, 515 to 617, 456 to 547, 611 to 825, 611 to 727, and 721 to 825)
were generated by PCR amplification with the mouse full-length DP103 plasmid
pcDNA3-DP103 (42) as a template (see Table 1 for primers). For VP16 fusion
proteins, PCR fragments were cloned downstream from the VP16 transactivation
domain at the BamHI-PstI sites in a pVP16 vector (Clontech). For GAL4 fusion
proteins, PCR fragments as described above as well as aa 1 to 617 and 1 to 727
were cloned downstream from GAL4 DNA binding domain (DBD) (amino acids
1 to 147) at the BamHI-PstI sites within the pM1 vector. Full-length p68 was
cloned from human placental cDNA by using primers F-ATGTCGGGTTAT-
TCGAGTGAC and R-TTATTGGGAATATCCTGTTGG and was cloned
downstream from GAL4 DBD at the BamHI-HindIII sites within the pM2
vector. A similar approach was utilized for generation of His-tagged DP103
constructs, with in-frame subcloning at BamHI-PstI sites of pQE32 or at BamHI-
BglI sites of PQE16 expression vectors (Qiagen Inc.). The activity of GAL4
fusion constructs was assessed by using either the reporter plasmid GKI, which
contains five GAL4 binding sites upstream of the E1B-TATA promoter, or
GAL4  5-tkLuc, which contains five GAL4 binding sites upstream of the
thymidine kinase minimal promoter; both were linked to luciferase. SF-1 activity
was measured by using SF-1 luciferase reporter S25 as well as P450scc (a gift
from J. S. Richards, Baylor College of Medicine, Houston, Tex.), as previously
described (7, 42).
Cell culture and transfections. CV-1 and JEG3 cells were maintained and
passaged as previously described (12). Adrenocortical Y1 cells were maintained
in Dulbecco’s modified Eagle medium with 10% fetal bovine serum and antibi-
otics at 37°C and 10% CO2. Cells were transfected by using the modified calcium-
phosphate method described previously (8), which included 0.05 g of cytomeg-
alovirus (CMV)–-galactosidase plasmid (to normalize for cell viability and
transfection efficiency). Standard luciferase assays were performed 48 h after
transfection as previously described (12) by using a Lumistar 96-well plate reader
(BMG, Durham, N.C.). All experiments were performed in duplicate and were
repeated at least three times. Results (means  standard deviations [SD]),
normalized to -galactosidase activity, were expressed as relative luciferase units
(cRLU). For Y1 RNA, cells were seeded in 6-well plates at a density of 150,000
cells/well. One day after transfection the cells were rinsed and cultured in me-
dium containing 0.1 M adrenocorticotropin (ACTH; Sigma) or water vehicle
and were harvested for total RNA 24 h later. One day after transfection the cells
were rinsed and cultured in medium containing 0.1 M ACTH (Sigma) or water
vehicle and were harvested for total RNA 24 h later.
Protein-protein interaction assay. His-tagged DP103 fragments, described
above, were expressed in Escherichia coli strain XL-1 Blue (Stratagene) and were
induced for 4 h at 37°C with 1 mM isopropyl--D-thiogalactopyranoside (IPTG).
Cells were harvested and resuspended in lysis buffer (50 mM NaH2PO4 [pH 8.0],
0.5 M NaCl, 10 mM -mercaptoethanol, 1% Tween 20, 10% glycerol, 15 mM
imidazole) and then were incubated with 1 mg of lysozyme/ml for 30 min on ice,
sonicated, and centrifuged at 15,000  g at 4°C. The supernatant (soluble frac-
tion) was saved for protein purification. The pellet was solubilized in a buffer
containing 1.5% Sarkosyl, 25 mM triethanolamine, 1 mM EDTA, 2% Triton
X-100, 1 mM CaCl2, and 15 mM imidazole. The pellet was then centrifuged and
the supernatant was again stored. His-tagged proteins were purified with Ni-
nitrilotriacetic acid (NTA) resin (Qiagen Inc.) under native conditions. The
supernatant was applied to an appropriate volume of 50% slurry of Ni-NTA
agarose resin and was gently mixed at 4°C for 1.5 h. The bound His-tagged
proteins were washed three times by using gradients of 0.8, 8, and 20 mM
imidazole in washing buffer (50 mM NaH2PO4 [pH 8.0], 0.5 M NaCl, 10 mM
-mercaptoethanol, 20% glycerol, and 2% Triton X-100) and were batch-eluted
by increasing the imidazole concentration to 500 mM. Purified His-tagged DP103
fragments were concentrated by using a Centricon centrifugal filter (Millipore).
SF-1 wild type and SF-1 mAAEY were in vitro translated and were labeled with
[35S]methionine by using TNT (Promega). For the in vitro protein-protein in-
teraction assay the His-tagged DP103 fragments bound to Ni-NTA agarose resin
were equilibrated in 70 l of binding buffer (20 mM Tris-HCl [pH 8.0], 100 mM
NaCl, 1 mM EDTA, and 0.5% NP-40). Five microliters of [35S]Met-labeled SF-1
was added for 2 h at 4°C. The resin was washed four times with 800 l of washing
buffer supplemented with 40 mM imidazole. Bound proteins were released by
boiling for 5 min, resolved on sodium dodecyl sulfate–10% polyacrylamide gel
electrophoresis (SDS–10% PAGE), and visualized by autoradiography. As con-
trols, 5 l of in vitro-translated SF-1 wild type or SF-1 mAAEY was reacted with
Ni2-NTA resin alone.
Expression analysis and hormone level. Total cellular RNA was isolated from
Y1 cells by using TRIzol (Life Technologies, Inc.) following the manufacturer’s
instructions and was incubated with DNase I (1 U/10 g of RNA; Ambion, Inc.)
at 37°C for 30 min and was inactivated with DNase Inactivation Reagent (Am-
bion) at room temperature for 2 min. The RNA was ethanol precipitated and
quantified. For quantitative PCR we initially performed reverse transcription
(RT) with 0.5 g of total RNA in a 50-l RT reaction (Applied Biosystems, Inc.)
TABLE 1. PCR primer sequences used to generate DP103













a Numbers denote first (F) or last (R) amino acid in fragment.
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which included 5 l of Taqman RT buffer, 11 l of 25 mM MgCl2, 10 l of 10
mM deoxynucleoside triphosphate mixture, 2.5 l of 50 M random primer, 20
U of RNase inhibitor, and 1.25 l of murine leukemia virus reverse transcriptase.
Transcript level was determined by quantitative PCR with a 5700 Sequence
Detector System (Applied Biosystems, Inc.). Each 50 l of PCR included 3 l of
RT products, forward primers, and reverse primers (Table 2) and 25 l of SYBR
Green master mixture (Applied Biosystems, Inc.). Transcript level was deter-
mined by using GeneAmp 5700 SDS software. For Western immunoblotting,
transfected CV-1 cells were lysed and protein concentration was determined as
previously described (50). Total cell lysate (30 g) was subjected to SDS–10%
PAGE, transferred to Immobilon-P transfer membrane (Millipore), and blotted
with primary mouse anti-GAL4DBD antibody (sc510; Santa Cruz) and horserad-
ish peroxidase-conjugated goat anti-mouse secondary antibody. The signal was
visualized by chemiluminescence (Amersham Pharmacia Biotech). A rabbit poly-
clonal antibody and a monoclonal antibody (Chemicon) were used for detection
of DP103 and P450scc, respectively. Protein levels were quantified with densi-
tometry (PhosphorImager; Molecular Dynamics, Inc.).
Progesterone levels (in nanograms per milliliter) in media from Y1 cells
transfected with the different DP103 plasmids were determined by using enzyme
immunoassay (Oxford Biomedical Research, Oxford, Mich.). Measurements
were performed in duplicate, each from a pair of wells identically transfected
48 h prior to analysis of hormone concentration.
Helicase assays. For generation of RNA strands, a pSV72 vector (Promega)
was first linearized with BamHI and was transcribed with SP6 polymerase in the
presence of [-32P]CTP (150 Ci) as recommended by the manufacturer (Pro-
mega), yielding a 50-nucleotide transcript from the polylinker of pSV72 (GAA
CTCGAGCAGCTGA AGCTTGCATGCCTGCAGGTCGACTCTAGAGGA
TC; the 15-bp duplex region is underlined). For the complementary strand,
pSV72 was linearized with AccI and was transcribed with T7 polymerase in the
presence of unlabeled nucleotides, yielding a 66-nucleotide transcript (GGGA
GACCGGCAGATCTGATATCATCGATGAATTCGAGCTCGGTACCCGG
GGATCCTCTAGAGTCG; the 15-bp duplex region is underlined). The two
strands were separated by using a denaturing 8 M urea–6% PAGE. The bands
were excised and eluted overnight in 0.5 M ammonium acetate, 1 mM EDTA,
and 0.1% SDS on a 4°C rotator. The DNA oligomers, which correspond to the
RNA oligomers described above, were purchased from Integrated DNA Tech-
nologies. The short DNA strand was [	-32P]ATP labeled by using T4 kinase (Life
Technologies, Inc.). RNA and DNA strands were phenol-chloroform extracted
and ethanol precipitated. Unlabeled long strands were annealed to labeled short
strands by gradual cooling from 95 to 37°C over 3 h in a mixture of 20 mM
HEPES, KOH (pH 7.2), 250 mM NaCl, and 1 mM EDTA. The annealed
substrates were resolved on a native 8% PAGE, excised, eluted, and ethanol
precipitated as described above and then were dissolved in diethyl pyrocarbon-
ate-treated H2O. The helicase assays were performed in 20 l of buffer (20 mM
Tris-HCl [pH 8.0], 70 mM KCl, 3 mM MgCl2, 2 mM dithiothreitol, 3 mM ATP,
20 U of RNasin, 200 g of bovine serum albumin/ml) by using partially duplexed
substrates (50 fmol) and 50 ng of purified His-tagged DP103. After 15 min of
incubation at 37°C the reaction was quenched with 5 l of stop solution (3%
SDS, 30% glycerol, and 150 mM EDTA). Reaction products were separated on
SDS–10% PAGE in 1 TBE (45 mM Tris-borate–1 mM EDTA) at 4°C and 160
V for 1.5 h. The gel was then dried and analyzed by using a PhosphorImager.
Double-stranded substrates, incubated at 37°C or boiled, served as negative and
positive controls, respectively.
RESULTS
The C-terminal domain of DP103 (aa 721 to 825) physically
interacts with SF-1. We have previously shown that DP103
directly interacts with the proximal repression domain (PRD)
of SF-1 (aa 193 to 201, Fig. 1A) and that mutations in PRD
significantly diminish this interaction (42). In addition, we have
demonstrated that the nonconserved C-terminal domain of
DP103 (aa 405 to 825, Fig. 1B) mediates the interaction with
SF-1 (42). To identify the specific region within DP103 that
mediates the interaction with SF-1 we generated a series of
DP103 C-terminal fragments, fused to the activation domain of
VP16, and tested for their interaction with GAL4-SF-1120-462
by employing a mammalian two-hybrid approach. As shown in
Fig. 1C, GAL4-SF-1120-462 chimeric protein interacted with
intact DP103 as well as with each DP103 fragment that har-
bored the C-terminal DP103721-825 region. Importantly, the
conserved N-terminal (aa 1 to 410) fragments of DP103 failed
to interact with SF-1. As expected, we found no interaction
between any DP103 construct and GAL4-SF-1120-462 that was
mutated in PRD (Fig. 1C). To obtain further support for the
direct interaction of DP103721-825 with SF-1 we examined the
interaction of the two proteins in vitro. For this purpose, we
tested the ability of resin-bound His-tagged DP103 fragments
to pull down wild-type or mutant 35S-labeled SF-1. As shown in
Fig. 2, only fragments 411 to 825 and 721 to 825 of DP103
interacted with 35S-labeled SF-1. The interaction was not ob-
served in the presence of mutant SF-1. Taken together,
DP103721-825 is required for the direct association of DP103
with SF-1.
The C-terminal domain of DP103 (aa 721 to 825) represses
SF-1 activity. We have previously demonstrated that DP103
represses the transcriptional activity of SF-1. We therefore
sought to determine if DP103 contains an intrinsic repression
domain. For this purpose we fused full-length DP103 or a
series of DP103 fragments to GAL4 and determined the ability
of these chimeric proteins to regulate the transcriptional ac-
tivity of a GAL4 reporter plasmid. As shown in Fig. 3A, only
GAL4-DP103 chimeric constructs that contained aa 721 to 825
(411 to 825, 611 to 825, and 721 to 825) repressed reporter
activity. The repression was concentration dependent, and the
degree of repression was similar to that of GAL4 fused to
full-length DP103. In contrast, GAL4-DP103 constructs span-
ning aa 1 to 410, 411 to 617, 1 to 617, 611 to 727, or 1 to 727
did not repress the GAL4 reporter. To confirm an equivalent
expression of transfected GAL4-DP103 constructs we used
Western immunoblotting to analyze the expression of these
chimeric proteins in CV-1 cells. The expression of GAL4-
DP103 constructs was uniform (Fig. 3B), indicating that the
differences in transcriptional activity represent transcriptional
repression function of DP103 fragments. As a control we also
demonstrated that a chimeric protein of GAL4 DBD fused to
the DEAD-box protein p68, which has been shown to enhance
the activity of the estrogen receptor (17), did not repress the








a F, forward sequence; R, reverse sequence.
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transcriptional activity of a GAL4 reporter plasmid (Fig. 3C).
Taken together these findings indicate that aa 721 to 825 of
DP103, which directly interact with SF-1, harbor a transcrip-
tional repression domain.
Having localized the repression domain of DP103 to aa 721
to 825, a domain that interacts with SF-1, we hypothesized that
DP103721-825 is necessary and sufficient for repression of SF-1.
We tested this hypothesis by utilizing two approaches. We
initially analyzed the effect of DP103721-825 on reporter gene
activation by SF-1. For this purpose we cotransfected JEG3
cells with an SF-1 expression plasmid, along with increasing
concentrations of either GAL4-DP1031-825, GAL4-DP103721-825,
or GAL4-DP1031-727 expression plasmids and the SF-1 syn-
thetic reporter S25, which contains two SF-1 binding elements
(TCAAGGTCA) upstream from the luciferase gene (12). As
shown in Fig. 4A, the repression domain at DP103721-825 re-
pressed SF-1 activity in a concentration-dependent manner,
reproducing the repression by intact DP103. There was no
effect on basal promoter activity in the absence of SF-1 (Fig.
4B). The estrogen receptor coactivator GAL4-p68 did not re-
press SF-1 activity (data not shown). We repeated the experi-
ment with the rat P450scc-Luc promoter. This promoter binds
SF-1 at positions
79 (SCC2) and
51 (SCC1) and is activated
by coexpressed SF-1 (7, 9). As expected, coexpression of either
GAL4-DP1031-825 or GAL4-DP103721-825, but not GAL4-
DP1031-727, diminished P450scc-Luc activity (Fig. 4C). In the
FIG. 1. DP103 interacts with the PRD in SF-1 (aa 193 to 201) through aa 721 to 825. (A) Schematic diagram depicting the main transcriptional
regulatory domains of SF-1. A mutated PRD, known to abrogate SF-1 repression, is shown. (B) A diagram of DP103, denoting eight highly
conserved motifs within the N-terminal region of DEAD-box family proteins as well as the nonconserved C-terminal region. (C) DP103721-825
interacts with wild type SF-1 but not with PRD mutant SF-1. Interaction was detected by using a mammalian two-hybrid assay, with SF-1120-462
fused downstream from GAL4 and DP103 fragments (as shown) fused to the VP16 activation domain. Plasmids were transiently transfected into
CV-1 cells along with the GAL4 reporter plasmid GKI. Results represent three independent experiments performed in duplicate, expressed as
fold activation over control in which the empty VP16 plasmid was used and normalized to -galactosidase activity.
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absence of SF-1 there was no repression of basal promoter
activity. Similarly, there was no effect of DP103 constructs on
the P450scc promoter that was mutated at both SF-1 binding
elements (Fig. 4D).
In a second approach, we analyzed the influence of
DP103721-825 on physiological targets for SF-1 in Y1 adreno-
cortical cells. These cells express SF-1 and DP103 endog-
enously (42), and steroid production by these cells is inducible
by ACTH (44, 59). We determined the influence of overex-
pressed DP103 on the expression of P450scc, P450c21, and
StAR, measured by quantitative real-time PCR. Transfection
of GAL4-DP1031-825 (3 g) led to a 2.4-fold increase in DP103
protein and resulted in a concentration-dependent reduction
in basal and ACTH-induced expression of P450scc and
P450c21 (Fig. 5A and B). A similar effect was observed with
overexpression of GAL4-DP103721-825 but not with GAL4-
DP1031-727, which is devoid of the repression domain. The
reduced expression of P450scc protein (twofold) was con-
firmed by Western analysis (data not shown). Interestingly,
there was no repression of StAR by any of the DP103 con-
structs (Fig. 5C). DP103 constructs did not affect SF-1 expres-
sion (Fig. 5D), indicating that the down-regulation of SF-1
targets could not be attributed to altered SF-1 expression. To
confirm the repressive effect of GAL4-DP1031-825 and GAL4-
DP103721-825 on steroidogenesis we measured progesterone
production by Y1 cells, transfected with the three GAL4-
DP103 expression plasmids. We found that the medium pro-
gesterone level was significantly reduced in Y1 cells transfected
with GAL4-DP1031-825 or GAL4-DP103721-825 but not GAL4-
DP1031-727 (Fig. 5E). The expression of DP103 was unchanged
by ACTH (data not shown). Together, our data clearly dem-
onstrate that DP103 represses the activity of SF-1 and that the
DP103721-825 domain is necessary and sufficient for this effect.
DP103 exhibits RNA helicase activity that requires its C-
terminal repression domain. The N-terminal region of DP103
(see Fig. 1B) is highly homologous with DEAD-box proteins
(6, 20, 42). This homologous region harbors a helicase domain
known to exhibit unwinding activity in other members of this
family (4, 25, 47, 54, 57, 70). We have thus far demonstrated
that the nonconserved C-terminal domain of DP103 interacts
with SF-1 and is necessary and sufficient for repression of
SF-1’s activity. We therefore questioned whether or not the
C-terminal domain is necessary for the helicase function of
FIG. 2. DP103721-825 physically interacts with SF-1’s PRD (aa 193
to 201) in vitro. Wild-type SF-1 (W) and PRD mutant SF-1 (M) cloned
in pBSK were expressed and labeled with [35S]methionine in vitro by
using a TNT transcription-translation system. Labeled SF-1 was incu-
bated with His-tagged DP103 fragments bound to Ni2-NTA agarose
resin. Bound SF-1 was detected by using SDS–10% PAGE and auto-
radiography. Input included 20% SF-1 that was used for each assay.
The empty Ni2-NTA agarose resin, reacted with wild-type or mutant
SF-1, served as negative control.
FIG. 3. DP103 harbors a repression domain at aa 721 to 825.
(A) CV-1 cells were cotransfected with increasing amounts (0, 0.03,
0.1, 0.3, 1.0, and 3.0 g) of either full-length DP103 or DP103 frag-
ments, fused to GAL4, along with the reporter plasmid GAL4 
5-tkLuc. Results (means  SD) are expressed as cRLU normalized to
-galactosidase activity and represent three independent experiments,
each performed in duplicate. (B) Western immunoblotting of the
GAL4-DP103 fusion proteins analyzed in panel A, demonstrating
equal cellular expression of transfected plasmids. Lysates (30 g) were
prepared from CV-1 cells that were transfected with 3 g of each
DP103 plasmid, separated by SDS-PAGE, and immunodetected by
using anti-GAL4 antibody as described in Materials and Methods.
(C) The DEAD-box protein p68 (3 g, expressed as chimeric protein
GAL4-p68) does not repress the reporter plasmid GAL4  5-tkLuc in
CV-1 cells. Results are means of three independent experiments, each
performed in duplicate, and are expressed as fold over control in which
the empty GAL4 plasmid was used.
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DP103. To address this question we first sought to determine
whether or not DP103 exhibits helicase activity. For that pur-
pose we generated several duplex oligonucleotides of RNA/
RNA, RNA/DNA, and DNA/DNA sequences, designed to
serve as DP103 substrates. We used bacterially expressed, His-
tagged purified DP103 as well as fragments aa 721 to 825 and
aa 1 to 727 to determine helicase activity by coincubation with
labeled duplex substrates (Fig. 6A). Using the RNA/RNA du-
plex substrate we initially determined optimal reaction condi-
tions. We found that full-length DP103 exhibited unwinding
activity, evident at a protein level as low as 3 ng. The reaction
was concentration dependent with complete unwinding using
50 ng of DP103 (Fig. 6B). The reaction was time dependent
and was maximal after 10 min (Fig. 6C). All subsequent reac-
tions were therefore performed over 15 min with 50 ng of each
protein. We next examined the helicase activity of the C-ter-
minal repression domain of DP103. As shown in Fig. 6D,
upper panel, while wild-type DP103 exhibited complete un-
winding of the RNA/RNA double-stranded substrate, there
was no such activity with DP103721-825 or DP1031-727 fragments
(Fig. 6D, lanes 3 to 5). Moreover, we were unable to reproduce
unwinding activity even when DP103721-825 and DP1031-727
fragments were coincubated in trans with the labeled duplex
substrate (Fig. 6D, lane 6). The RNA unwinding activity was
ATP dependent, as it was not observed in the absence of ATP
or in the presence of the nonhydrolyzable ATP analog ATP-
	-S (Fig. 6D, lanes 7 and 8). We reproduced these results with
RNA/DNA duplexes, demonstrating unwinding activity with
full-length DP103 but not with the fragments that span aa 721
to 825 or aa 1 to 727 (Fig. 6D, middle panel). In contrast, we
observed no DNA/DNA unwinding activity with any of the
proteins (compare lane 3 in the lower panel of Fig. 6D to the
FIG. 4. DP103721-825 represses the transcription of SF-1 target promoters. (A) The concentration-dependent influence of GAL4-fused full-
length or truncated DP103 on the transcriptional activity of SF-1. JEG3 cells were cotransfected with 0.05 g of CMV-SF-1 and either
GAL4-DP1031-825, GAL4-DP103721-825, or GAL4-DP1031-727 (0, 0.1, 0.3, 1.0, and 3.0 g), along with 0.5 g of the SF-1 luciferase reporter plasmid
S25. (B) The repression effect of DP103 is observed only in the presence of SF-1. Transfection was performed as described above, with 3 g of
GAL4-DP103721-825 or GAL4-DP1031-727. The empty expression vector CMV-neo or GAL4 was used as control for SF-1 and DP103, respectively.
(C) Concentration-dependent influence of GAL4-fused full-length or truncated DP103 on the transcriptional activity of an SF-1-responsive rat
P450scc reporter. Transfection was performed as described above, with 0.5 g of the SF-1 luciferase reporter plasmid P450scc. (D) SF-1 is required
for the repression effect of DP103. The repression was abrogated when the two SF-1 binding elements in the P450scc promoter were mutated.
Transfection was performed as described above. Results (means  SD) are expressed as cRLU normalized to -galactosidase activity and
represent three independent experiments, each performed in duplicate.
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same lane on the two other panels). We conclude that the
DEAD-box protein DP103 is capable of RNA helicase activity
and that the C-terminal domain at aa 721 to 825 is obligatory
but not sufficient for this activity of DP103.
DISCUSSION
Members of the DEAD-box family of putative RNA heli-
cases exhibit diverse cellular functions, including DNA tran-
scription, recombination and repair, RNA processing, transla-
tion, and posttranslational gene regulation, in eukaryotes and
prokaryotes (2, 10, 13, 21, 30, 58). Newly discovered proteins of
unknown function are added to this family on the basis of
homology with the DEAD-box, ATPase, or helicase domains.
Several of these proteins contain additional domains of un-
known function. DP103 was cloned by us and others on the
basis of its physical interaction with transcriptional regulators.
DP103 contains conserved DEAD-box, helicase, and ATPase
domains. In contrast, the C-terminal region of DP103 is not
conserved in other members of the DEAD-box family. We
have previously determined that DP103 binds a repression
domain within SF-1 and represses its activity (42). Our data
and the degree of repression are consistent with the findings of
Voss et al., who have recently demonstrated that DP103 re-
presses the transcriptional activation of the viral latent mem-
brane protein 1 promoter by the EBNA2/SMN complex in
FIG. 5. DP103721-825 diminishes the expression of SF-1 target genes in the adrenocortical line. Y1 cells were transfected with increasing
amounts (0, 1.0, and 3.0 g) of GAL4-DP1031-825, GAL4-DP103721-825, or GAL4-DP1031-727. Steroidogenesis was stimulated with 0.1 M of
ACTH or water vehicles 18 h after transfection. Total RNA was isolated and processed for quantitative RT-PCR as described in Materials and
Methods. (A) Expression of P450scc mRNA. (B) Expression of P450c21 mRNA. (C) Expression of StAR mRNA. (D) GAL4-DP103 fusion
proteins do not diminish the expression of SF-1. Results (means SD) are expressed as fold expression over control (no ACTH, no GAL4-DP103)
and represent three independent experiments, each performed in duplicate. (E) Progesterone levels in media from cultured Y1 cells transfected
with GAL4-DP103 plasmids (3 g) and collected over 24 h prior to hormone determination. Results (means  SD) are expressed as fold over
control (GAL4) and represent three to five independent experiments, each performed in duplicate. An asterisk denotes a P value of 0.05
(Student’s t test).
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B-lymphocytes (65). The repression was attenuated when a
DP103 binding-deficient SMN mutant was used (65). Here we
examined the repression function of DP103 and located the
interaction domain to aa 721 to 825 within the C terminus of
DP103. Consistent with our results, DP103 interacts with the
viral proteins EBNA2 and EBNA3C through the region span-
ning aa 666 to 824 (5, 20, 65). This region was also determined
to mediate the repression function of DP103 in a recent anal-
ysis of DP103 interaction with the Ets repressor METS (32).
Together, our data lead to the unexpected conclusion that the
C-terminal domain is necessary and sufficient for SF-1 inter-
action and repression of transcription, and hence the transcrip-
tional repression of SF-1 by DP103 does not require helicase
activity.
Having demonstrated DP103’s helicase activity we found
that the C-terminal domain is obligatory for RNA unwinding
activity of DP103, thereby establishing the pivotal role of this
domain in the dual function of DP103. Unlike the repression
function, the C-terminal domain is not sufficient for unwinding
activity, which requires additional domains within the con-
served N terminus. Interestingly, a similar role for a noncon-
served C-terminal domain was observed for the bacterial
DEAD-box helicases DbpA and YxiN, in which a unique C-
terminal domain binds to 23S rRNA, thus bestowing sequence
specificity and stimulating the nonspecific helicase activity of
the N-terminal conserved domains (14, 34, 60).
The regulation of SF-1 by the C-terminal domain of a
DEAD-box helicase constitutes a previously unidentified
mechanism for regulation of a nuclear receptor. This C-termi-
nal domain physically interacts with the proximal repression
domain of SF-1 and exhibits an autonomous repression func-
tion. This conclusion is supported by the fact that GAL4-
DP103721-825 is sufficient to repress a GAL4 reporter gene, and
DP103721-825 represses SF-1. Consistent with these findings, we
have previously demonstrated that DP103 represses the tran-
scriptional activity of an estradiol-stimulated estrogen receptor
fused to SF-1’s PRD (42). Importantly, the repression function
of DP103721-825 is observed by using relevant SF-1 reporter
constructs as well as P450scc and P450c21, known transcrip-
tional targets for SF-1 in adrenocortical cells. These results
cannot be explained by altered SF-1 expression, as its level is
unchanged by overexpressed DP103. Interestingly, although
SF-1 was shown to up-regulate the StAR promoter in vitro
(56), we found that DP103 failed to repress StAR expression.
The reason for this nonuniform influence of DP103 on SF-1
targets is unclear and may suggest that the interaction of SF-1
with DP103 is target selective. Interestingly, Bland et al. dem-
onstrated that StAR expression was not reduced in haploin-
sufficient SF-1 heterozygous mice (3), suggesting that SF-1 may
not play a dominant role in the regulation of StAR.
Whereas the biological activity of putative RNA helicases
has been demonstrated (12, 16, 28, 36, 54), ATP-dependent
RNA helicase activity has been characterized for only some of
these proteins (13, 14, 45, 46, 62, 63). Our data clearly indicate
that, similar to other RNA helicases (15, 45, 63), DP103 ex-
hibits RNA helicase activity in an ATP-dependent fashion and
in a 5 to 3 direction with a 5 single-strand overhang and is
thus distinguished from activity of DNA helicases (51, 54, 61).
Whether or not DP103 is capable of bidirectional unwinding
activity, as shown for several other helicases, is presently un-
known.
Our studies do not elucidate the mechanism of transcrip-
tional repression by DP103. Repression of unliganded nuclear
receptors is commonly mediated by N-CoR (SMRT)/mSin3/
histone deacetylase (HDAC) complexes (24, 40). Similarly, we
and others have demonstrated that DAX-1 can serve as an
adapter molecule that recruits the nuclear receptor corepres-
sor N-CoR to SF-1 (11, 27). A recent publication by Klap-
pacher et al. provides evidence that DP103 interacts with
METS to repress Ets by assembling a complex of N-CoR,
Sin3A, HDAC-2, and HDAC-5 (32). We could not demon-
strate an interaction between DP103 and DAX-1 (data not
shown). Whether or not this mechanism underlies the repres-
sion of SF-1 by DP103 is unclear. Although other DEAD-box
proteins regulate gene transcription, the involvement of heli-
FIG. 6. DP103 exhibits RNA helicase activity in vitro. Helicase
assays (533) were performed under standard conditions as described
in Materials and Methods, with 50 fmol of either 32P-labeled RNA/
RNA, RNA/DNA, or DNA/DNA duplex substrates, along with His-
tagged DP103 in the presence of ATP (3 mM) at 37°C. (A) The
structure of the artificial RNA or DNA duplex substrates. (B) RNA
helicase activity of DP103 is concentration dependent. A concentration
range of full-length His-tagged DP103 (0, 3, 10, 30, and 50 ng) was
examined. (C) A time course for the RNA helicase activity of full-
length DP103 at the time points indicated. (D) Helicase assay with 50
ng of proteins as indicated, along with RNA/RNA (upper panel),
RNA/DNA (middle panel), or DNA/DNA (lower panel) substrates.
ATP (3 mM) was present unless indicated as being absent or replaced
with ATP-	-S (3 mM). All the helicase assays were performed for 15
min. Boiled double-stranded (ds) substrates or substrate incubated
without protein at 37°C was used as control, indicating the position of
released single-stranded (ss) or ds probe, respectively. 32P-labeled
short ss probe was also included in the experiments depicted in panels
B and C to highlight the position of released ssRNA or ssDNA.
VOL. 23, 2003 BIFUNCTIONAL DOMAIN WITHIN DP103 421
 o
n
 January 6, 2014 by W








case function in this process is inconsistent (1, 18, 41, 55, 64).
One example is RHII/Gu, in which RNA helicase activity is
involved in c-Jun-activated transcription during neuronal dif-
ferentiation of PC12 cells (67). Because residues between aa
721 to 825 in DP103 are pivotal in conferring specificity to
DP103 tethering, it is also conceivable that this region may
sequester a transactivating cofactor or may disrupt a transcrip-
tionally active nucleic acid-protein complex (29), resulting in
diminished transcriptional activation. Moreover, the fact that
helicase activity was not recapitulated when both DP1031-727
and DP103721-825 were coexpressed in trans suggests that the
C-terminal domain modulates intramolecular conformation of
DP103, paramount for interaction with additional protein
complexes and unwinding activity. Dissecting these mecha-
nisms in vitro and in vivo is imperative for our understanding
of the physiological role of helicase activity and chromatin
remodeling.
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